Program #2 - Ki67 Testing in HR+/HER2- EBC: Education and Resources for Oncology and Pathology Healthcare Teams

Credits: AMA, ANCC, ACPE

Learning Objectives:

- Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
- Evaluate the clinical validity, utility, and differences among Ki67 assessment techniques
- Integrate best practices for Ki67 testing methodology, standardization, and reporting
- Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Foster collaborative discussions and workflows between oncologists, pathologists and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
- Identify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trials